Related references
Note: Only part of the references are listed.Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia
Lian Xu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
Panagiotis Baliakas et al.
BLOOD (2015)
High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates
Irina Bonzheim et al.
BLOOD (2015)
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells
Yang Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
Janine Schmidt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A novel MYD88 mutation, L265RPP, in Waldenstrom macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival
T. Nagao et al.
BLOOD CANCER JOURNAL (2015)
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia
Y. Cao et al.
LEUKEMIA (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
Aldo M. Roccaro et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
Alejandra Martinez-Trillos et al.
BLOOD (2014)
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
Stephanie Poulain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance
James Q. Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
S. Jeromin et al.
LEUKEMIA (2014)
Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
L. Xu et al.
LEUKEMIA (2014)
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia
S. Weber et al.
BLOOD CANCER JOURNAL (2014)
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia
Stephanie Poulain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
BLOOD (2013)
A new era for Waldenstrom macroglobulinemia: MYD88 L265P
Steven P. Treon et al.
BLOOD (2013)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
The genomic landscape of chronic lymphocytic leukemia: clinical implications
Victor Quesada et al.
BMC MEDICINE (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
The molecular profile of adult T-cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL
Vera Grossmann et al.
GENES CHROMOSOMES & CANCER (2013)
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Vera Grossmann et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas
N. Gachard et al.
LEUKEMIA (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL
Wolfgang Kern et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia
Wolfgang Kern et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2012)
Molecular pathogenesis of Waldenstrom's macroglobulinemia
Esteban Braggio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
Correlation of Flow Cytometrically Determined Expression of Zap-70 Using the SBZAP Antibody with IgVH Mutation Status and Cytogenetics in 1,229 Patients with Chronic Lymphocytic Leukemia
Wolfgang Kern et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
Comprehensive genetic characterization of CLL:: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping
C. Haferlach et al.
LEUKEMIA (2007)
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients:: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression
Frank Dicker et al.
BLOOD (2006)
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
ZR Hunter et al.
CLINICAL LYMPHOMA (2005)
Share Paper
